[HTML][HTML] Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses

A Agarwal, CA Vieira, BK Book, RA Sidner… - American Journal of …, 2004 - Elsevier
Pre-formed HLA antibodies (Ab), reported as panel-reactive antibody (PRA), prolong
transplant waiting time. We hypothesized that rituximab (RIT) could reduce PRA via B-cell
depletion. As part of a Phase I study of single RIT dose, we studied in vivo and ex vivo
effects on T-cell immune responses. Nine subjects (n= 3) were treated at 50, 150, and 375
mg/m 2. Serum interleukin-1α (IL-1α), IL-6, IL-12, tumor necrosis factor beta (TNF-β), and
interferon-gamma (IFN-γ) were measured by enzyme-linked immunosorbent assay (ELISA) …